

Mitesh J Borad

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8473936/publications.pdf](https://exaly.com/author-pdf/8473936/publications.pdf)

Version: 2024-02-01

149
papers

13,850
citations

53202

45
h-index

24808

110
g-index

235
all docs

235
docs citations

235
times ranked

20407
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. <i>Cancer Research Communications</i> , 2024, 4, 1165-1173.	1.8	0
2	Introducing the PLOS collection on rare cancer. <i>PLoS ONE</i> , 2024, 19, e0308087.	2.5	0
3	Perspectives of primary care providers regarding multicancer early detection panels. <i>Einstein (Sao) Tj ETQq1 1 0.784314 rgBT₀/Overlo</i>	0.7	0
4	Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma. <i>Molecular Therapy - Oncolytics</i> , 2023, 29, 4-14.	4.4	1
5	Epigenomics May Begin To Explain <i><i>In Vitro</i></i> Differential Response To Hypomethylating Agents In MMR-D Hypermethylated Endometrial Cancer. <i>Epigenomics</i> , 2023, 15, 283-292.	2.1	1
6	The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2023, , .	3.2	2
7	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	13.7	47
8	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e508-e528.	4.7	42
9	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	2.7	22
10	Synergistic combination of cytotoxic chemotherapy and cyclinâ€¢dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	8.1	6
11	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 81-90.	2.7	3
12	Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. <i>Cancer Prevention Research</i> , 2022, 15, 121-128.	1.6	12
13	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	2.4	5
14	Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 125-131.	4.0	12
15	Isocitrate Dehydrogenaseâ€¢Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. <i>JCO Precision Oncology</i> , 2022, 6, e2100156.	3.2	12
16	Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 288-297.	1.4	6
17	Reply to A. Rizzo et al. <i>JCO Precision Oncology</i> , 2022, 6, e2200061.	3.2	0
18	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	15.4	118

#	ARTICLE	IF	CITATIONS
19	Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opinion on Investigational Drugs, 2022, 31, 1-13.	4.0	8
20	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers, 2022, 14, 2056.	3.8	25
21	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	3.2	5
22	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precision Oncology, 2022, , .	3.2	11
23	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 2021, 39, 1072-1080.	2.7	5
24	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 2021, 12, 1930.	13.2	9
25	Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers, 2021, 13, 1186.	3.8	3
26	Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist, 2021, 26, 569-578.	4.1	24
27	Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precision Oncology, 2021, 5, 733-743.	3.2	13
28	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. JCO Precision Oncology, 2021, 5, 432-441.	3.2	19
29	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	3.7	10
30	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 2021, 13, 2968.	3.8	80
31	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	3.2	4
32	P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology, 2021, 32, S333.	1.3	2
33	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. Journal of Hepatology, 2021, 75, 351-362.	3.9	39
34	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.8	211
35	Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 641044.	2.9	2
36	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/III Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	15.4	303

#	ARTICLE	IF	CITATIONS
37	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. <i>Genome Biology</i> , 2021, 22, 227.	9.2	17
38	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.3	247
39	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with <i>FGFR2</i> fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	8.2	246
40	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 11-11.	1.3	9
41	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	2.5	19
42	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .	1.2	13
43	Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103535.	4.5	14
44	ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. <i>Science Advances</i> , 2021, 7, eabl8213.	10.9	118
45	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	2.9	8
46	Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy. <i>Mayo Clinic Proceedings</i> , 2020, 95, 306-318.	2.8	7
47	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	7.3	75
48	Second-line therapies in advanced biliary tract cancers. <i>Lancet Oncology</i> , The, 2020, 21, e29-e41.	10.8	80
49	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. <i>Oncologist</i> , 2020, 25, 380-e763.	4.1	10
50	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	1.8	18
51	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	7.3	144
52	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	2.4	108
53	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	1.8	12
54	Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. <i>Cancer Research</i> , 2020, 80, 4324-4334.	0.9	40

#	ARTICLE	IF	CITATIONS
55	Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells. <i>Journal of Hepatology</i> , 2020, 73, S122.	3.9	5
56	Updated data from an ongoing study with ADP-A2AFP spear T-cells. <i>Journal of Hepatology</i> , 2020, 73, S910-S911.	3.9	1
57	Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. <i>Hepatology Communications</i> , 2020, 4, 1781-1792.	4.4	9
58	Ivrosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.8	690
59	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. <i>JCO Precision Oncology</i> , 2020, 4, 557-569.	3.2	38
60	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	10.8	1,044
61	Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. <i>Hpb</i> , 2020, 22, 1490-1495.	0.3	15
62	Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. <i>European Journal of Surgical Oncology</i> , 2020, 46, 789-795.	1.0	16
63	Advances in the treatment of biliary tract cancers. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 85-89.	2.3	10
64	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	6.6	525
65	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1063-1078.	2.4	15
66	Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 546-555.	4.4	11
67	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	30.1	332
68	Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 501-504.	1.2	0
69	HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. <i>Hepatology</i> , 2019, 69, 131-142.	8.1	27
70	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 745-750.	1.4	17
71	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 554-561.	1.4	35
72	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]. <i>Oncolytic Virotherapy</i> , 2019, Volume 8, 1-2.	6.0	0

#	ARTICLE	IF	CITATIONS
73	Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecularâ€‘clinical analysis and potential targeted approach. <i>Hepatology International</i> , 2019, 13, 490-500.	4.4	40
74	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	7.3	354
75	Hepatocytes direct the formation of a pro-metastatic niche in the liver. <i>Nature</i> , 2019, 567, 249-252.	36.2	283
76	MetaMarker: a pipeline for <i>de novo</i> discovery of novel metagenomic biomarkers. <i>Bioinformatics</i> , 2019, 35, 3812-3814.	4.2	12
77	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1432-1438.	1.0	73
78	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	1.2	34
79	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 684-692.	2.7	33
80	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 379-386.	0.3	12
81	Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. <i>Translational Oncology</i> , 2019, 12, 143-153.	3.8	38
82	E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. <i>Investigational New Drugs</i> , 2019, 37, 636-645.	2.7	24
83	Novel Targeted Therapy Strategies for Biliary Tract Cancers and Hepatocellular Carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	2.4	23
84	Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). <i>International Journal of Surgery</i> , 2018, 52, 171-179.	3.6	39
85	Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 153-161.	6.6	59
86	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2018, 67, 2338-2351.	8.1	96
87	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.2	108
88	Phase II Study of BGJ398 in Patients With <i>FGFR</i> -Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	15.4	554
89	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1054-1062.	1.4	117
90	Emerging role of precision medicine in biliary tract cancers. <i>Npj Precision Oncology</i> , 2018, 2, 21.	5.5	30

#	ARTICLE	IF	CITATIONS
91	Novel Immunotherapy Strategies for Hepatobiliary Cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	2.0	6
92	Chromoanasythesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. <i>BMC Cancer</i> , 2018, 18, 738.	2.6	14
93	Oncolytic Adenoviruses in Gastrointestinal Cancers. <i>Biomedicines</i> , 2018, 6, 33.	3.3	9
94	Prevalent hepatitis B surface antigen among first-time blood donors in Gabon. <i>PLoS ONE</i> , 2018, 13, e0194285.	2.5	18
95	Exploring the Role of Oncolytic Viruses in Hepatobiliary Cancers. <i>Immunotherapy</i> , 2018, 10, 971-986.	2.0	9
96	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e727-e734.	1.9	3
97	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). <i>Targeted Oncology</i> , 2017, 12, 201-209.	3.7	25
98	Immunotherapy in pancreatic cancer treatment: a new frontier. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 168-194.	3.2	75
99	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	6.3	443
100	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	2.7	671
101	Quantitative Imaging System for Cancer Diagnosis and Treatment Planning: An Interdisciplinary Approach. , 2017, , 152-175.		4
102	Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	4.1	30
103	Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1583-1591.	2.8	24
104	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 127-132.	1.4	4
105	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 19, 2878-2880.	6.3	158
106	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	2.1	57
107	Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. <i>Diagnostics</i> , 2017, 7, 50.	2.8	10
108	Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations. <i>Journal of Clinical Medicine</i> , 2017, 6, 26.	2.5	23

#	ARTICLE	IF	CITATIONS
109	Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 39-49.	6.0	33
110	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 11-18.	6.0	32
111	Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. <i>Cureus</i> , 2017, 9, e1517.	0.5	2
112	The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 789-796.	1.4	28
113	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016, 34, 96-103.	2.7	2
114	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. <i>Cancer Letters</i> , 2016, 380, 163-173.	7.3	75
115	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. <i>Scientific Reports</i> , 2016, 6, 25.	3.4	34
116	Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. <i>Cancer Investigation</i> , 2016, 34, 57-63.	1.3	0
117	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 439-447.	3.7	86
118	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 264-268.	2.3	48
119	Oncolytic viruses: perspectives on clinical development. <i>Current Opinion in Virology</i> , 2015, 13, 55-60.	5.6	19
120	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	7.2	40
121	IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-sensitive mechanism. <i>Hepatology</i> , 2015, 61, 1627-1642.	8.1	121
122	A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. <i>Cancer Investigation</i> , 2015, 33, 172-179.	1.3	4
123	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1475-1481.	15.4	156
124	Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements. <i>PLoS ONE</i> , 2014, 9, e87113.	2.5	15
125	Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2014, 34, 456-464.	3.7	113
126	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	3.4	298

#	ARTICLE	IF	CITATIONS
127	Immunotherapeutic and Oncolytic Viral Therapeutic Strategies in Pancreatic Cancer. <i>Future Oncology</i> , 2014, 10, 1255-1275.	2.4	5
128	Detecting the micro-defects in the GaAs materials by time resolved emissions. <i>Science Bulletin</i> , 2014, 59, 1838-1844.	1.6	2
129	Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 931-941.	2.4	29
130	Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 710-716.	2.7	46
131	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014, 45, 1630-1638.	2.3	247
132	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 718-721.	2.8	15
133	Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. <i>Investigational New Drugs</i> , 2013, 31, 1056-1065.	2.7	6
134	Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 934-941.	2.3	17
135	A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etrinetecan Pegol in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 268-278.	7.2	48
136	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1092-1100.	7.2	81
137	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 2334-2343.	2.7	32
138	The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials. <i>Journal of Cancer</i> , 2012, 3, 345-353.	2.6	17
139	2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen. <i>Blood</i> , 2012, 120, 4723-4723.	1.4	0
140	Effects of Elevation on Litter-Size Variation Among Lizard Populations in the <i>Sceloporus grammicus</i> Complex (Phrynosomatidae) in Mexico. <i>Western North American Naturalist</i> , 2011, 71, 215-221.	0.4	22
141	Multiplexed genotyping of beta globin mutations with MALDI-TOF mass spectrometry. <i>Clinica Chimica Acta</i> , 2011, 412, 999-1002.	1.6	6
142	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 2502-2511.	7.2	503
143	Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. <i>Cancer</i> , 2011, 117, 3276-3283.	4.1	4
144	Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3431-3442.	7.2	29

#	ARTICLE	IF	CITATIONS
145	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 2997-3004.	7.2	136
146	Reply to M. Buyse et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e453-e453.	15.4	2
147	Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon- β in Rodents and Nonhuman Primates. <i>Human Gene Therapy</i> , 2010, 21, 451-462.	3.0	65
148	Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4877-4883.	15.4	563
149	Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2009, 361, 1164-1172.	30.1	1,060